Latest Depression News

Page 5 of 11
Actinogen Medical has secured an initial $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending, bolstering funding for its Alzheimer’s and depression drug trials.
Ada Torres
Ada Torres
15 Oct 2025
Tryptamine Therapeutics has enrolled the first patient in its pioneering clinical trial testing TRP-8803, an IV-infused psilocin formulation, for Binge Eating Disorder. The study aims to evaluate safety and efficacy, potentially reshaping treatment options for millions.
Ada Torres
Ada Torres
14 Oct 2025
OD6 Metals has initiated Phase 2 drilling at its Gulf Creek Copper Project in NSW, aiming to explore large geophysical anomalies and untested prospects that could expand on previously confirmed high-grade copper mineralisation.
Maxwell Dee
Maxwell Dee
14 Oct 2025
QEM Limited’s latest metallurgical tests have upended key assumptions of its 2024 Julia Creek Scoping Study, prompting a strategic review amid a tough vanadium market. The company now questions the viability of direct kerogen flotation for vanadium recovery and shifts focus to capital preservation and project reassessment.
Maxwell Dee
Maxwell Dee
23 Sept 2025
Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.
Ada Torres
Ada Torres
22 Sept 2025
Burgundy Diamond Mines posted a $29.5 million net loss for H1 2025, driven by operational disruptions and weaker diamond prices, leading to a temporary halt of mining at Point Lake. The company is navigating liquidity challenges with new financing arrangements while restructuring its operations.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.
Ada Torres
Ada Torres
29 Aug 2025
RPM Automotive Group reported a mixed FY25 with a slight revenue decline but improved profitability and launched a tyre recycling initiative signaling a strategic shift.
Victor Sage
Victor Sage
28 Aug 2025
Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.
Ada Torres
Ada Torres
28 Aug 2025
Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.
Ada Torres
Ada Torres
26 Aug 2025
Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.
Ada Torres
Ada Torres
25 Aug 2025
Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.
Ada Torres
Ada Torres
25 Aug 2025